» Articles » PMID: 37664167

The Hypertension-based Chronic Disease Model in a Primary Care Setting

Abstract

Background: Driver-based chronic disease models address the public health challenge of cardiometabolic risk. However, there is no data available about the novel Hypertension-Based Chronic Disease (HBCD) model. This study investigates the prevalence, characteristics, and prognostic significance of HBCD Stages in a primary care cohort.

Methods: This study included participants aged ≥45 years, randomly selected from the primary care program of a Brazilian medium-sized city. Participants underwent electrocardiogram, tissue Doppler echocardiogram and were followed for a median of 6 years. Participants were classified into HBCD Stages as follows: Stage 1: hypertension risk factors; Stage 2: pre-hypertension; Stage 3: hypertension; and Stage 4: hypertension complications.

Results: Overall, 633 participants were included in the cross-sectional analysis and 560 that had follow-up data were included in the prognostic analysis. From 633 participants, 1.3% had no identifiable risk factors for HBCD, 10.0% were Stage 1, 14.7% Stage 2, 51.5% Stage 3, and 22.5% Stage 4. Increasing HBCD stages had worse glomerular filtration rates, echocardiographic markers, and higher body mass index, waist circumference, blood glucose levels, and prevalence of type 2 diabetes. Rates of all-cause mortality or cardiovascular hospitalization increased across HBCD Stages: Stage 1: 3.6%; Stage 2: 4.8%, Stage 3: 7.6%; and Stage 4: 39.5%. Kaplan-Meier curves showed composite outcome worsened across HBCD Stages 1-4 (p < 0.001).

Conclusions: HBCD is a conceptually and prognostically valid model. Remarkably, HBCD stages were associated with progressively worsening markers of heart disease, declining kidney function and higher rates of all-cause mortality or cardiovascular hospitalization.

Citing Articles

Bayesian network model of ethno-racial disparities in cardiometabolic-based chronic disease using NHANES 1999-2018.

Babagoli M, Beller M, Gonzalez-Rivas J, Nieto-Martinez R, Gulamali F, Mechanick J Front Public Health. 2024; 12:1409731.

PMID: 39473589 PMC: 11519814. DOI: 10.3389/fpubh.2024.1409731.

References
1.
Mechanick J, Farkouh M, Newman J, Garvey W . Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(5):525-538. PMC: 7187687. DOI: 10.1016/j.jacc.2019.11.044. View

2.
Beaney T, Schutte A, Stergiou G, Borghi C, Burger D, Charchar F . May Measurement Month 2019: The Global Blood Pressure Screening Campaign of the International Society of Hypertension. Hypertension. 2020; 76(2):333-341. DOI: 10.1161/HYPERTENSIONAHA.120.14874. View

3.
Kim M, Lim N, Park H . Relationship between prehypertension and chronic kidney disease in middle-aged people in Korea: the Korean genome and epidemiology study. BMC Public Health. 2012; 12:960. PMC: 3549294. DOI: 10.1186/1471-2458-12-960. View

4.
Mechanick J, Garber A, Grunberger G, Handelsman Y, Garvey W . DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2019; 24(11):995-1011. DOI: 10.4158/PS-2018-0139. View

5.
Correia E, Mechanick J, Barbetta L, Lagoeiro Jorge A, Mesquita E . Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure. Heart Fail Rev. 2022; 28(1):47-61. DOI: 10.1007/s10741-022-10233-x. View